The influence of aldosterone and anticonvulsant drugs on electroencephalographic and clinical disturbances induced by the spirolactone derivative, potassium canrenoate.
D000450:Aldosterone / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects; D003975:Diazepam / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004285:Dogs; D004569:Electroencephalography; D004827:Epilepsy / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D008297:Male; D010672:Phenytoin / Q000627:therapeutic use; D013148:Spironolactone / Q000008:administration & dosage / Q000009:adverse effects / Q000032:analysis*
D000927:Anticonvulsants; D013148:Spironolactone; D000450:Aldosterone; D010672:Phenytoin; D003975:Diazepam